Ying D Song

US Patent:

6638709, Oct 28, 2003

Filed:

Dec 26, 2001

Appl. No.:

10/032929

Inventors:

Hsin-Chien Tai - Hackensack NJ
Alla Laufer - Brooklyn NY
Ying Song - Franklin Park NJ
Nitya G. Ray - East Hanover NJ

Assignee:

Ortec International, Inc. - New York NY

International Classification:

A01N 102

US Classification:

435 13, 623 2372

Abstract:

Processes are described for making a cryopreserved Composite Living Construct (CCLC) as well as a corresponding thawed and rinsed CCLC, comprised of separated layers of cultured fibroblasts and cultured keratinocytes, wherein the percent of cells that are viable, i. e. , the cell viability, of such CCLC is at least about 70 %. The viable cell density in the CCLC is at least about 50% of that before cryopreservation. The storage stability of the CCLC is at least about 12 months. Additionally, the metabolic activity of thawed and rinsed CCLC is at least about 50% of the Composite Living Construct (CLC) before cryopreservation. The structural integrity of CCLC is substantially the same as the CLC before cryopreservation. The process for making the CCLC comprises the steps of: providing a collagen substrate comprised of a collagen sponge layer and a nonporous to cells, semipermeable collagen layer; seeding and culturing, in the presence of a cell growth medium, fibroblasts on and within the collagen sponge layer and keratinocytes on the nonporous to cells, semipermeable collagen layer, thereby providing a CLC; equilibrating the CLC, according to a defined equilibration program with a cryoprotectant solution comprising at least chondroitin sulfate and dimethylsulfoxide; lowering the temperature, according to a programmed rate, to about -90Â C. ; and storing the CCLC at about -150Â C. or lower.

US Patent:

6645715, Nov 11, 2003

Filed:

Jul 24, 2000

Appl. No.:

09/624909

Inventors:

May Griffith - Ottawa, CA
Mitchell Watsky - Arlington TN
Charles J. Doillon - Québec, CA
Ying Song - Philadelphia PA

Assignee:

University of Ottawa - Ottawa
Universite Laval - Quebec City
University of Tennessee Research Corp. - Knoxville TN

International Classification:

A01N 102

US Classification:

435 11, 435371, 623 511, 623 516

Abstract:

The invention provides an in vitro avascular human corneal equivalent that comprises immortalized human cell lines. As these corneal equivalents are in vitro models, they are maintained in an incubator throughout the testing period, thereby eliminating the problems and expense associated with animal care. The corneal equivalent is preferably surrounded by a matrix in which angiogenesis (formation of capillary-like structures) can occur in vitro. This surrounding matrix has the potential to play the role of a pseudo-sclera, allowing the in vitro assessment of the corneas angiogenic reaction to any substance or injury. Furthermore, the model is capable of being produced easily, is physiologically functional and can give predictable and quantifiable results when submitted to various drugs, chemicals and/or physical trauma. Modifications can be made, such as the use of primary donor cells instead of cell lines; and the physical and chemical treatments of the matrix material to make the constructs suitable for use in transplantation.

US Patent:

20040053409, Mar 18, 2004

Filed:

Aug 15, 2003

Appl. No.:

10/641655

Inventors:

Hsin-Chien Tai - Hackensack NJ, US
Alla Laufer - Brooklyn NY, US
Ying Song - Franklin Park NJ, US
Nitya Ray - East Hanover NJ, US

Assignee:

Ortec International, Inc. - New York NY

International Classification:

C12N005/08

US Classification:

435/374000, 435/397000

Abstract:

Processes are described for making a cryopreserved Composite Living Construct (CCLC) as well as a corresponding thawed and rinsed CCLC, comprised of separated layers of cultured fibroblasts and cultured keratinocytes, wherein the percent of cells that are viable, i.e., the cell viability, of such CCLC is at least about 70%. The viable cell density in the CCLC is at least about 50% of that before cryopreservation. The storage stability of the CCLC is at least about 12 months. Additionally, the metabolic activity of thawed and rinsed CCLC is at least about 50% of the Composite Living Construct (CLC) before cryopreservation. The structural integrity of CCLC is substantially the same as the CLC before cryopreservation. The process for making the CCLC comprises the steps of: providing a collagen substrate comprised of a collagen sponge layer and a nonporous to cells, semipermeable collagen layer; seeding and culturing, in the presence of a cell growth medium, fibroblasts on and within the collagen sponge layer and keratinocytes on the nonporous to cells, semipermeable collagen layer, thereby providing a CLC; equilibrating the CLC, according to a defined equilibration program with a cryoprotectant solution comprising at least chondroitin sulfate and dimethylsulfoxide; lowering the temperature, according to a programmed rate, to about -90 C.; and storing the CCLC at about -150 C. or lower. The process for preparing the CCLC to treat wounds in humans and in animals additionally comprises programmed thawing as well as a rinsing sequence to substantially remove the cryoprotectants.

US Patent:

20180044384, Feb 15, 2018

Filed:

Feb 17, 2017

Appl. No.:

15/436204

Inventors:

Xiu-Min LI - Mamaroneck NY, US
Zhenwen Zhou - Guangdong, CN
Zhigang LIU - Guangdong, CN
Ying SONG - Rego Park NY, US

International Classification:

C07K 14/28
C12N 15/70
C12R 1/63
C12N 1/20

Abstract:

The present disclosure provides compositions comprising recombinant bacterial spores. The present disclosure is also directed to vaccine based compositions, which include recombinant bacterial spores that express CTB and a peanut protein(s) on their surfaces. This disclosure also provides methods for administering these compositions as a treatment or prevention of peanut allergy.

US Patent:

20160175291, Jun 23, 2016

Filed:

Sep 17, 2015

Appl. No.:

14/857772

Inventors:

Xiu-Min Li - Mamaroneck NY, US
Nan Yang - Flushing NY, US
Chaoyi Mao - Beijing, CN
Ying Song - Elmhurst NY, US

International Classification:

A61K 31/4375
A61K 31/122
A61K 31/366

Abstract:

The present invention relates to compounds and formulations derived from traditional Chinese medicine for use for the treatment and/or mediation of food allergies, in particular peanut allergies in humans by altering the activity and/or production of IgE.